Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q1 2024 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.29824 EPS, expectations were $0.09. Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals Inc. (AMRX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rubric Capital Management David Rosen | 9,541,948 | $57,824,205 | +20% | 1.7% |
| 2. | Citadel Investment Group Ken Griffin | 5,067,483 | $30,708,947 | -23% | 0% |
| 3. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 2,619,943 | $15,876,855 | +13% | 0.9% |
| 4. | Blackbarn Capital Jonathan Carter | 1,413,297 | $8,564,580 | 4.84% | |
| 5. | AQR Capital Management Cliff Asness | 756,387 | $4,583,705 | -9% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.21 | 50,000 | Director | 258,784 | 2021-12-17 | Filing | |
| $4.25 | 50,000 | Large Shareholder, Officer, Director | 512,566 | 2021-12-16 | Filing | |
| $4.13 | 100,000 | Large Shareholder, Officer, Director | 462,566 | 2021-12-15 | Filing | |
| $4.25 | 50,000 | Officer, Director | 512,566 | 2021-12-16 | Filing | |
| $4.13 | 100,000 | Officer, Director | 462,566 | 2021-12-15 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.73 | 23,447 | Director | 93,402 | 2024-05-17 | Filing | |
| $6.76 | 14,553 | Director | 116,849 | 2024-05-16 | Filing | |
| $4.13 | 29,302 | Officer | 244,739 | 2023-08-11 | Filing | |
| $2.34 | 3,884,600 | Other | 12,328,767 | 2022-12-12 | Filing | |
| $3.95 | 2,000 | Officer | 212,996 | 2021-12-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 21,521,301 | $130,634,297 | 26.61% | |
| 2. | 13,642,387 | $82,809,287 | 0% | |
| 3. | 12,328,767 | $74,835,616 | 1.2% | |
| 4. | 8,846,421 | $53,697,775 | 0% | |
| 5. | 3,741,007 | $22,717,998 | 0.01% |
News See All
11 Best Small Cap Pharma Stocks to Invest In
In this piece, we will take a look at the 11 best small cap pharma stocks to invest in.
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q4 2023 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.14, expectations were $0.07.
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q3 2023 Earnings Call Transcript
Anthony DiMeo: Good morning, and thank you for joining Amneal Pharmaceuticals Third Quarter 2023 Earnings Call. Today, we issued a press release reporting our Q3 results.
5 Best Fast Growing Penny Stocks to Buy Now
Additive electronics and hardware products company Nano Dimension Ltd. (NASDAQ:NNDM) ranks 5th in our list of the best fast growing penny stocks to buy now. In early July, Nano Dimension Ltd.
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q2 2023 Earnings Call Transcript
Operator: Hello, everyone and welcome to the Amneal Pharmaceuticals Second Quarter 2023 Earnings Conference Call. My name is Bruno, and I’ll be operating your call today.
Top 20 Countries With Highest Drug Consumption
In this piece, we will take a look at the top 20 countries with the highest drug consumption.
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q1 2023 Earnings Call Transcript
Operator: Hello, everyone and welcome to the Amneal Pharmaceuticals First Quarter 2023 Earnings Conference Call. My name is Emily, and I'll be your moderator for today's call.
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q4 2022 Earnings Call Transcript
Operator: Hello, everyone. And welcome to the Amneal Fourth Quarter 2022 Earnings Conference Call. My name is Bruno, and I'll be operating your call today.
10 Best 52-Week Low Small-Cap Stocks to Buy Now
In this article, we discuss the 10 best 52-week low small-cap stocks to buy now.
Billionaire Hedge Funds
